Thermo Fisher and Datavant Forge Alliance to Reshape Drug Research

WALTHAM, MA – February 11, 2026 – In a significant move to accelerate the future of medicine, Thermo Fisher Scientific has announced a strategic collaboration with Datavant, a leading healthcare data platform. The partnership, driven by Thermo Fisher’s PPD™ clinical research business, is set to break down long-standing barriers between clinical trial data and real-world data (RWD), promising to help pharmaceutical and biotech companies generate stronger evidence and bring new therapies to patients more quickly.

This alliance aims to tackle one of the most persistent challenges in drug development: data fragmentation. Historically, the information gathered in controlled clinical trials has remained separate from the vast ocean of RWD generated daily through electronic health records, insurance claims, and patient registries. By integrating these disparate sources, the collaboration seeks to create a more holistic picture of a patient's health journey, thereby enhancing the design, recruitment, and execution of clinical studies.

The New Frontier of Evidence Generation

The core of the collaboration lies in leveraging Datavant's advanced technology for privacy-preserving data linkage. Datavant enables the secure connection of patient-level data across its extensive network, which includes over 350 RWD partners and data from 80,000 U.S. hospitals and clinics. This is accomplished through a process called “tokenization,” which converts sensitive personal information into a unique, encrypted, and non-identifiable token.

This token acts as a key, allowing researchers to link a patient's records from different sources—such as a clinical trial dataset and their electronic medical records—without ever exposing or transferring the underlying personal data. The result is a richer, longitudinal view of patient health that maintains strict confidentiality. For Thermo Fisher’s clients, this means the ability to enrich clinical trial data with real-world context, leading to more robust insights into a drug's safety and efficacy.

“Data interoperability is critical to the next generation of evidence generation,” said Karen Kaucic, M.D., president of patient and advisory services and chief medical officer for clinical research at Thermo Fisher Scientific. “By enabling privacy-protected data connectivity at scale, this collaboration allows us to deliver a more seamless and efficient research experience for our customers.”

Balancing Innovation with Ironclad Privacy

As the use of big data in healthcare expands, so do concerns about patient privacy and data security. The partnership directly addresses these ethical considerations by building on a foundation of proven, privacy-centric technology. Datavant’s platform is designed to be fully compliant with stringent regulations like the Health Insurance Portability and Accountability Act (HIPAA), ensuring that all data linkage activities adhere to the highest legal and ethical standards.

The tokenization process is fundamental to this security framework. Because the original patient identifiers are never shared between data holders, the risk of a breach or re-identification is significantly minimized. This approach allows the life sciences industry to harness the power of large-scale data analytics while upholding its responsibility to protect patient confidentiality.

“This collaboration with Thermo Fisher underscores Datavant’s role in enabling secure, privacy-preserving data connectivity at scale,” stated Arnaub Chatterjee, GM and President of Life Sciences at Datavant. “By combining Datavant’s trusted data linkage technology with Thermo Fisher’s deep clinical research expertise and infrastructure, we’re helping bring richer, more connected patient data into the research process.” He added that reducing friction across the research lifecycle is key for partners to “generate insights faster and advance better outcomes for patients.”

A Strategic Pillar in a Broader Digital Overhaul

This collaboration is not an isolated event but a calculated move within Thermo Fisher's broader digital transformation strategy. The company, a giant in the life sciences sector with annual revenues exceeding $40 billion, has been making aggressive investments to embed artificial intelligence and advanced data analytics across its entire portfolio. This initiative follows a previously announced partnership with OpenAI, signaling a clear intent to lead the industry's technological evolution.

By integrating Datavant's capabilities, Thermo Fisher strengthens its PPD clinical research business, which provides services for drug development. The move enhances its offerings in the rapidly growing fields of Real-World Evidence (RWE), patient registries, and observational studies. These services are increasingly vital as regulatory bodies like the FDA show greater acceptance of RWE in their decision-making processes.

“By integrating Datavant’s capabilities with Thermo Fisher’s data, digital and AI capabilities, we can help our customers accelerate insights and ultimately improve patient outcomes,” noted Krishna Cheriath, vice president and head of digital and AI for biopharma services at Thermo Fisher Scientific. “This collaboration represents another milestone in our continued investment in digital transformation to accelerate innovation for our customers.”

The Tangible Impact on Trials and Patient Care

The ultimate goal of this partnership is to translate technological innovation into tangible benefits for patients. For pharmaceutical companies, the ability to securely link data can dramatically improve the efficiency of clinical trials. Researchers can more easily identify eligible participants, particularly for rare diseases where patients are scarce. This can significantly speed up recruitment, a common bottleneck that delays the development of new treatments.

Furthermore, by creating more connected studies, companies can gain deeper insights into how a drug performs in a real-world setting, beyond the pristine conditions of a randomized controlled trial. This can lead to better safety monitoring, a more nuanced understanding of long-term effects, and the development of more targeted, personalized therapies.

For patients, the implications are profound. A more efficient drug development pipeline means that life-saving medications can potentially reach the market years sooner. The ability to leverage RWD also supports the creation of more diverse and inclusive trials, ensuring that new treatments are tested on populations that better reflect the real world. As the industry continues its shift toward data-driven medicine, collaborations like the one between Thermo Fisher and Datavant are becoming essential infrastructure for building a healthier future.